Full Title
An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy Of AB-2100 in Patients with Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CCRCC)Purpose
The purpose of this study is to find the best dose of AB-2100 cellular therapy for people with clear cell renal cell cancer (CCRCC). The people in this study have CCRCC that came back or spread after treatment.
AB-2100 is a type of immunotherapy made from your own white blood cells called T cells. If you join this study, we will collect some of your T cells. We will then add a gene that will help your T cells find and kill your cancer cells. These genetically changed T cells are called integrated circuit T (ICT) cells. Treatments made from them are called ICT therapies. AB-2100 and the other medications used in this study are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have CCRCC that came back or spread after treatment.
- Have completed prior anti-cancer treatments at least 2 weeks before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Ritesh Kotecha’s office at 646-422-4839.